ScandiBio Therapeutics
ScandiBio Therapeutics is a Swedish biotechnology company that leverages Artificial Intelligence and Systems Biology to develop novel treatment strategies for metabolic diseases and mitochondrial dysfunction. Their platform integrates omics data, genome-scale metabolic models, and biological networks to analyze clinical data and identify targets. The company is developing metabolic co-factors and has several clinical studies in progress, including trials for COVID-19, AD/PD (neurological diseases), and NAFLD (fatty liver disease). Their approach aims to treat the root causes of diseases rather than just symptoms, with a focus on improving patient outcomes through data-driven medicine.
ScandiBio Therapeutics
ScandiBio Therapeutics is a Swedish biotechnology company that leverages Artificial Intelligence and Systems Biology to develop novel treatment strategies for metabolic diseases and mitochondrial dysfunction. Their platform integrates omics data, genome-scale metabolic models, and biological networks to analyze clinical data and identify targets. The company is developing metabolic co-factors and has several clinical studies in progress, including trials for COVID-19, AD/PD (neurological diseases), and NAFLD (fatty liver disease). Their approach aims to treat the root causes of diseases rather than just symptoms, with a focus on improving patient outcomes through data-driven medicine.